506,706 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Purchased by William Blair Investment Management LLC

William Blair Investment Management LLC acquired a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 506,706 shares of the company's stock, valued at approximately $12,252,000. William Blair Investment Management LLC owned about 0.23% of Hims & Hers Health at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. State Street Corp lifted its stake in Hims & Hers Health by 4.7% in the third quarter. State Street Corp now owns 4,626,543 shares of the company's stock valued at $85,221,000 after purchasing an additional 206,078 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Hims & Hers Health by 12.7% in the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock valued at $79,029,000 after buying an additional 482,177 shares during the period. Wellington Management Group LLP raised its stake in shares of Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock valued at $63,446,000 after buying an additional 883,230 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Hims & Hers Health by 7.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company's stock valued at $43,448,000 after buying an additional 129,416 shares during the last quarter. Finally, Yong Rong HK Asset Management Ltd purchased a new stake in Hims & Hers Health in the 4th quarter worth about $41,104,000. Institutional investors own 63.52% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 target price for the company. Leerink Partners raised their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Piper Sandler increased their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 25th. Finally, Canaccord Genuity Group raised their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $37.31.

Hims & Hers Health Stock Up 7.5 %

NYSE:HIMS traded up $2.62 during midday trading on Monday, hitting $37.37. The company had a trading volume of 26,319,367 shares, compared to its average volume of 13,886,103. The company has a market capitalization of $8.30 billion, a PE ratio of 84.92 and a beta of 1.37. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The stock's fifty day moving average price is $39.21 and its 200-day moving average price is $28.89.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to analysts' expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Patrick Harrison Carroll sold 23,287 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total value of $798,976.97. Following the completion of the sale, the insider now owns 209,661 shares of the company's stock, valued at approximately $7,193,468.91. The trade was a 10.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Oluyemi Okupe sold 4,213 shares of the firm's stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $29.98, for a total value of $126,305.74. Following the transaction, the chief financial officer now owns 128,365 shares in the company, valued at approximately $3,848,382.70. The trade was a 3.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,015,547 shares of company stock valued at $36,146,450. 17.71% of the stock is currently owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.